ACCG-2671 Updated Nov 12
ACCG-2671 is a very early-stage (Phase 1/2a) oral amylin receptor agonist for obesity. The single-dose data from September 2026 showed a ~6-day half-life, up to 3.3% body weight loss, and no serious adverse events in 31 healthy adults. The next catalyst is the MAD (multiple ascending dose) data expected in 1H 2027, which will show whether the weight-loss signal persists with repeat dosing. Investors should watch for whether the MAD data confirms a competitive profile versus other oral amylin agonists in development at Novo Nordisk and others.
- Oral formulation could be a major advantage over injectable obesity drugs if efficacy is confirmed in later trials.
- The ~6-day half-life suggests potential for weekly or less-frequent oral dosing, which would be differentiated.
- Up to 3.3% weight loss in a single-dose study in healthy non-obese adults is an encouraging early signal, especially with no serious adverse events.
- ACCG-2671 is very early stage (Phase 1/2a SAD only); the 3.3% weight loss came from a single dose in only 31 healthy non-obese adults, not a repeat-dose obesity study.
- The MAD data (1H 2027) is the real test; single-dose weight loss often does not translate to sustained, clinically meaningful weight reduction.
- The obesity market is intensely competitive with Novo Nordisk (Wegovy, oral amycretin), Eli Lilly (Zepbound, orforglipron), and others far ahead in development.